Anti-Human HIF1A Monoclonal Antibody (1A712) (HS858015)

Name: Anti-Human HIF1A Monoclonal Antibody (1A712)
Brand: abinScience
SKU: HS858015
Price: 106 USD
Availability: InStock

데이터시트 제품 공유 정보 복사

가격(USD):

사양:

20ug
50ug
100ug

수량:

문의하기

개요
이미지
참고 문헌
데이터시트
SDS

개요

카탈로그 번호	HS858015
설명	Anti-Human HIF1A Monoclonal Antibody (1A712) [1A712] (HS858015) is a mouse monoclonal antibody detecting HIF1A in ELISA, IHC, WB. Suitable for Human. Highlights ●Recombinant — Superior batch-to-batch reproducibility with defined sequences. ●Multi-Application — Validated across multiple applications.
종 반응성	Human
응용 분야	ELISA, IHC, WB
숙주 종	Mouse
클론성	Monoclonal
이소타입	IgG
클론 ID	1A712
면역원	E. coli - derived recombinant human HIF1A (Asp55-Val342).
타겟	Hypoxia-inducible factor 1-alpha, HIF-1-alpha, HIF1-alpha, ARNT-interacting protein, Basic-helix-loop-helix-PAS protein MOP1, Class E basic helix-loop-helix protein 78, bHLHe78, Member of PAS protein 1, PAS domain-containing protein 8, HIF1A
정제	Protein A/G purified from cell culture supernatant.
등록번호	Q16665
형태	Liquid
저장 완충액	0.01M PBS pH 7.4 데이터시트 인쇄본 또는 로트별 COA에 기재된 구체적인 완충액 정보를 참조하세요.
안정성 및 저장	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
배경	Hypoxia-inducible factor 1-alpha (HIF1A) is a ~92 kDa protein. Functions as a master transcriptional regulator of the adaptive response to hypoxia. Under hypoxic conditions, activates the transcription of over 40 genes, including erythropoietin, glucose transporters, glycolytic enzymes, vascular endothelial growth factor, HILPDA, and other genes whose protein products increase oxygen delivery or facilitate metabolic adaptation to hypoxia. Plays an essential role in embryonic vascularization, tumor angiogenesis and pathophysiology of ischemic disease. Heterodimerizes with ARNT; heterodimer binds to core DNA sequence 5'-TACGTG-3' within the hypoxia response element (HRE) of target gene promoters. Activation requires recruitment of transcriptional coactivators such as CREBBP and EP300. 1. Jaakkola, P. et al. (2001) Science (New York, N.Y.) 292, 468-72. PMID: 11292861 2. Masson, N. et al. (2001) The EMBO journal 20, 5197-206. PMID: 11566883 3. Bae, SH. et al. (2004) Biochemical and biophysical research communications 324, 394-400. PMID: 15465032 4. Choi, SM. et al. (2006) The Journal of biological chemistry 281, 34056-63. PMID: 16973622 5. Berta, MA. et al. (2007) Biochemical and biophysical research communications 360, 646-52. PMID: 17610843 6. Kim, EJ. et al. (2008) Arteriosclerosis, thrombosis, and vascular biology 28, 1796-802. PMID: 18658046 7. Gimm, T. et al. (2010) FASEB journal : official publication of the Federation of American Societies for Experimental Biology 24, 4443-58. PMID: 20624928 8. Shan, B. et al. (2012) Endocrine-related cancer 19, 13-27. PMID: 22009797 9. Xu, C. et al. (2018) PLoS pathogens 14, e1007259. PMID: 30125331 10. Bhattacharya, S. et al. (1999) Genes & development 13, 64-75. PMID: 9887100
참고사항	For research use only.